#China #Nanjing #Drug Development #CMC Strategy #PharmaBlock

Enhancing Drug Development Efficiency at the PharmaBlock CMC Lifecycle Strategy Forum

PharmaBlock recently convened industry leaders at the CMC Lifecycle Strategy Forum in Nanjing, China, on November 5 and 6. The event gathered experienced professionals from the pharmaceutical development sector to discuss innovative strategies for enhancing the drug development lifecycle. With a focus on smarter, stage-appropriate Chemistry, Manufacturing, and Controls (CMC) decisions, the forum aimed to boost the efficiency of drug development programs while ensuring readiness for both clinical trials and commercialization.

The Gathering of Experts

At the forum, participants included seasoned R&D experts from major pharmaceutical companies such as AstraZeneca, AbbVie, Bayer, and Pfizer, along with representatives from notable biotechnology firms like Seda Pharmaceutical, Jacobio Pharma, and Benemae. This diverse mix of industry talent facilitated rich discussions about various aspects of drug development, including chemical and drug product development, solid-state science, and the practical applications of model-informed drug development.

As the landscape for biopharmaceuticals evolves, the need for companies to effectively navigate the global stage is paramount. Many Chinese biotech firms are now leveraging international partnerships and out-licensing opportunities to enhance their global reach. Amidst these changes, key factors such as developability, process maturity, and quality readiness have emerged as critical in determining whether a developmental program can successfully proceed through the necessary stages to commercialization.

The Importance of Stage-Appropriate CMC Strategies

The recurring theme at the forum was that effective CMC strategies are defined not merely by the volume of work undertaken but by the quality and relevance of that work in moving a development program forward. Yaohui Ji, Senior Vice President and Head of CDMO Business at PharmaBlock, emphasized the importance of understanding a program's current status and the requirements for upcoming milestones. This insight ensures that the right expertise and evidence are applied at the correct stages of development.

Early in the drug development process, teams should prioritize candidate developability, the properties of active pharmaceutical ingredients (API), formulation performance, and the overall fit-for-purpose clinical supply. As a program matures, the focus must shift towards gaining a deeper understanding of the production processes and products, establishing analytical control strategies, facilitating technology transfers, and ensuring reliable commercial supply chains.

Impact of Chemical Route and Processes on Development

Discussions also highlighted the critical effects that decisions surrounding chemical routes and processes can have on the timelines of development, scale-up activities, manufacturing costs, and the future supply of the product. By utilizing model-informed drug development principles, participants discussed how key properties of APIs, alongside formulation performance and pharmacokinetics, can be linked to inform decisions regarding dose selection and product development.

The panel discussions at the forum translated theoretical concepts into tangible applications in the pharmaceutical space. Topics covered included candidate selection processes, formulation strategies, drug exposure assessments, and the readiness for partnerships. This practical approach aimed to cultivate better collaboration opportunities in the fast-paced world of drug development.

Insights from Practical Visits

Ahead of the forum, attendees had the opportunity to tour the PharmaBlock Research Institute and the PharmaBlock OPC R&D Center in Nanjing. These visits showcased the company’s pioneering work in continuous flow chemistry, high-throughput experimentation, and process analytical technologies, reinforcing PharmaBlock’s extensive capabilities in areas such as oligonucleotide synthesis, peptide production, and the development of complex conjugates.

As a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO), PharmaBlock offers a comprehensive suite of services that encompass every stage of drug development – from early discovery through to commercial manufacturing. The purpose of the CMC Lifecycle Strategy Forum was to bridge the gap between global drug development expertise and China's innovative biotechnology ecosystem, helping companies produce the right evidence at critical junctures as they progress through clinical milestones and enter the global market.

In conclusion, the PharmaBlock CMC Lifecycle Strategy Forum exemplified a vital gathering of minds in the biopharmaceutical realm, fostering discussions that promise to shape the future of drug development strategies and partnerships on a global scale.